Aravive Investor Presentation Deck

Next Steps for PDAC To identify the RP2D: - Amend the current P1b study to test 6 patients at 20 mg/kg batiraxcept + gemcitabine + nab-paclitaxel to determine if: • a greater proportion of patients have batiraxcept trough levels above the minimum efficacious exposure; clinical activity is higher with this dose Depending on the pk and response data, may add another 6 patients at this dose or escalate to 25mg/kg Biomarker (SAXL/GAS6) will be assessed at the RP2D 34

View entire presentation